Mereo BioPharma Group plc is a biotechnology business based in the UK. Mereo BioPharma Group shares (MPH.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 31p – a decrease of 8.01% over the previous week. Mereo BioPharma Group employs 50 staff and has a market cap (total outstanding shares value) of £89.8 million.
Since the stock market crash in March caused by coronavirus, Mereo BioPharma Group's share price has had significant positive movement.
Its last market close was 31p, which is 0.00% up on its pre-crash value of 31p and 138.46% up on the lowest point reached during the March crash when the shares fell as low as 13p.
If you had bought £1,000 worth of Mereo BioPharma Group shares at the start of February 2020, those shares would have been worth £666.67 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,148.15.
|Latest market close||31p|
|52-week range||16p - 60p|
|50-day moving average||32p|
|200-day moving average||40.837p|
|Wall St. target price||705p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-43p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2020-12-17)||12.60%|
|3 months (2020-10-16)||-18.06%|
|6 months (2020-07-17)||-34.66%|
|1 year (2020-01-17)||-7.81%|
|2 years (2019-01-17)||-83.66%|
|3 years (2018-01-17)||-90.87%|
|Gross profit TTM||£0|
|Return on assets TTM||-20.81%|
|Return on equity TTM||-344.02%|
|Market capitalisation||£89.8 million|
TTM: trailing 12 months
We're not expecting Mereo BioPharma Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Mereo BioPharma Group's shares have ranged in value from as little as 16p up to 60p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Mereo BioPharma Group's is 0.7463. This would suggest that Mereo BioPharma Group's shares are less volatile than average (for this exchange).
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
Ever wondered how to buy shares in ULS Technology? We explain how and compare a range of providers that can give you access to many brands, including ULS Technology.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.